Receptors, Vascular Endothelial Growth Factor

"Receptors, Vascular Endothelial Growth Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A family of closely related RECEPTOR PROTEIN-TYROSINE KINASES that bind vascular endothelial growth factors. They share a cluster of seven extracellular IG-LIKE DOMAINS which are important for ligand binding. They are highly expressed in vascular endothelial cells and are critical for the physiological and pathological growth, development and maintenance of blood and lymphatic vessels.

Descriptor ID	D040262
MeSH Number(s)	D08.811.913.696.620.682.725.400.950 D12.776.543.750.630.750 D12.776.543.750.750.400.910
Concept/Terms	Receptors, Vascular Endothelial Growth Factor Receptors, Vascular Endothelial Growth Factor Receptor, Vascular Endothelial Cell Growth Factor Receptor, Vascular Permeability Factor VEGF Receptors Receptors, VEGF Vascular Endothelial Cell Growth Factor Receptor VPF Receptor Vascular Endothelial Growth Factor Receptor VEGF Receptor Vascular Permeability Factor Receptor Endothelial Growth Factor Receptor Endothelial Growth Factor Receptor Receptor, Endothelial Growth Factors

Below are MeSH descriptors whose meaning is more general than "Receptors, Vascular Endothelial Growth Factor".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
Phosphotransferases [D08.811.913.696]
Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
Protein Kinases [D08.811.913.696.620.682]
Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
Receptors, Vascular Endothelial Growth Factor [D08.811.913.696.620.682.725.400.950]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
Receptors, Vascular Endothelial Growth Factor [D12.776.543.750.630.750]
Receptors, Peptide [D12.776.543.750.750]
Receptors, Growth Factor [D12.776.543.750.750.400]
Receptors, Vascular Endothelial Growth Factor [D12.776.543.750.750.400.910]

Below are MeSH descriptors whose meaning is related to "Receptors, Vascular Endothelial Growth Factor".

Below are MeSH descriptors whose meaning is more specific than "Receptors, Vascular Endothelial Growth Factor".

Receptors, Vascular Endothelial Growth Factor
Vascular Endothelial Growth Factor Receptor-1
Vascular Endothelial Growth Factor Receptor-2
Vascular Endothelial Growth Factor Receptor-3

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Receptors, Vascular Endothelial Growth Factor" by people in this website by year, and whether "Receptors, Vascular Endothelial Growth Factor" was a major or minor topic of these publications.

Bar chart showing 24 publications over 17 distinct years, with a maximum of 3 publications in 2006 and 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	0	1	1
2002	0	1	1
2005	0	1	1
2006	1	2	3
2008	0	2	2
2009	1	0	1
2011	0	1	1
2012	0	1	1
2013	0	2	2
2014	1	1	2
2015	0	1	1
2016	1	2	3
2018	1	0	1
2019	0	1	1
2021	0	1	1
2022	0	1	1
2023	0	1	1

Below are the most recent publications written about "Receptors, Vascular Endothelial Growth Factor" by people in Profiles.

Archambault SD, Nichols MM, McCullum JC, Zhang Y, Steinberger EE, Ramsey DJ. Patient adherence to therapy after switch to aflibercept from bevacizumab or ranibizumab for treatment-refractory neovascular age-related macular degeneration. Indian J Ophthalmol. 2024 Jan 01; 72(Suppl 1):S101-S105.

View in: PubMed
Lally DR, Loewenstein A, Arnold JJ, Yang YC, Gedif K, Best C, Patel H, Tadayoni R, Heier JS. Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies. Eye (Lond). 2023 04; 37(6):1242-1248.

View in: PubMed
Basso U, Procopio G, Fornarini G, Massari F, Bearz A, Fratino L, Milella M, Bassanelli M, Ermacora P, Bimbatti D, Verzoni E, Rizzo M, Porta C. Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16). Oncology. 2021; 99(12):747-755.

View in: PubMed
Ramsey DJ, McCullum JC, Steinberger EE, Zhang Y, Alwreikat AM, Cooper ML, Roh S, Cotran PR. Intraocular pressure decreases in eyes with glaucoma-related diagnoses after conversion to aflibercept for treatment-resistant age-related macular degeneration. Eye (Lond). 2022 09; 36(9):1813-1819.

View in: PubMed
Mercurio AM. VEGF/Neuropilin Signaling in Cancer Stem Cells. Int J Mol Sci. 2019 Jan 23; 20(3).

View in: PubMed
Santoni M, Massari F, Piva F, Carrozza F, Di Nunno V, Cimadamore A, Martignetti A, Montironi R, Battelli N. Tivozanib for the treatment of renal cell carcinoma. Expert Opin Pharmacother. 2018 Jun; 19(9):1021-1025.

View in: PubMed
Mittal K, Derosa L, Albiges L, Wood L, Elson P, Gilligan T, Garcia J, Dreicer R, Escudier B, Rini B. Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors. Clin Genitourin Cancer. 2018 06; 16(3):e663-e667.

View in: PubMed
Toledano S, Lu H, Palacio A, Ziv K, Kessler O, Schaal S, Neufeld G, Barak Y. A Sema3C Mutant Resistant to Cleavage by Furin (FR-Sema3C) Inhibits Choroidal Neovascularization. PLoS One. 2016; 11(12):e0168122.

View in: PubMed
Moshfeghi DM, Hariprasad SM, Marx JL, Thompson D, Soo Y, Gibson A, Saroj N, Vitti R, Heier JS. Effect of Fluid Status at Week 12 on Visual and Anatomic Outcomes at Week 52 in the VIEW 1 and 2 Trials. Ophthalmic Surg Lasers Imaging Retina. 2016 Mar; 47(3):238-44.

View in: PubMed
Goel HL, Pursell B, Shultz LD, Greiner DL, Brekken RA, Vander Kooi CW, Mercurio AM. P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer. Cell Rep. 2016 Mar 08; 14(9):2193-2208.

View in: PubMed

People

Explore

Similar Concepts

Top Journals